Wilson disease with hepatic presentation in an eight-month-old boy

Kuerbanjiang Abuduxikuer1, Li-Ting Li1, Yi-Ling Qiu1

  • 1Kuerbanjiang Abuduxikuer, Li-Ting Li, Yi-Ling Qiu, Jian-She Wang, Liver Center, Children's Hospital of Fudan University, Shanghai 200032, China.

Insights

Wilson disease, a genetic copper metabolism disorder, can be fatal if untreated. This report details the youngest diagnosed patient, an 8-month-old Chinese boy, highlighting the need for early detection and treatment.

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Pediatrics

Background:

  • Wilson disease is an inherited autosomal recessive disorder affecting copper metabolism.
  • Untreated Wilson disease can lead to severe neurological and hepatic complications.
  • Early diagnosis and intervention are crucial for managing Wilson disease.

Observation:

  • An 8-month-old Chinese boy presented with elevated liver enzymes and low serum ceruloplasmin.
  • Genetic analysis identified two heterozygous mutations in the ATP7B gene (c.2621C>T/p.A874V and c.3809A>G/p.N1270S).
  • This case represents the youngest reported patient with elevated liver enzymes due to Wilson disease.

Findings:

  • The patient's persistent elevation of serum aminotransferase normalized after zinc therapy.
  • Genetic testing confirmed compound heterozygous mutations in the ATP7B gene.
  • Parental origin of the mutations was established.

Implications:

  • This case underscores the importance of early Wilson disease diagnosis in infants presenting with liver enzyme abnormalities.
  • Increased pediatrician awareness can lead to timely diagnosis and treatment, improving patient outcomes.
  • Zinc therapy demonstrated efficacy in normalizing liver enzymes in this young patient.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
8.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K